Skip to Main text
Nitto always aims for fair disclosure to ensure that our investors can properly evaluate our corporate value.
|2017/Jan/11||Nitto Named One of the 2016 Top 100 Global IP/Patents-related Innovators, Marking its Sixth Consecutive Year on the List|
|2016/Dec/26||2017/Jan/31 Announcement of Financial Results for 3Q, FY2016|
|2016/Nov/11||Bristol-Myers Squibb Signs Exclusive Worldwide License Agreement with Nitto Denko for Targeted siRNA Therapy in Advanced Non-alcoholic Steatohepatitis (NASH) and Cirrhosis Due to NASH|
Back to Page Top